Sexual and urinary morbidities resulting from treatment of pelvic malignancies are common. Awareness of these complications is critical in order to properly counsel patients regarding potential side effects and to facilitate prompt diagnosis and management.
Men who receive testosterone replacement therapy had an increased rate of favorable-risk prostate cancer compared to those who did not use the therapy, and a decreased rate of aggressive prostate cancer.
In this video, Dr. Nicholas David James discusses the results of the STAMPEDE trial, which tested front-line docetaxel combined with hormonal therapy in patients with advanced, hormone-naive prostate cancer.
Dr. Morris discusses results and implications of the CHAARTED trial, which studied the survival impact of androgen deprivation therapy (ADT) plus docetaxel vs ADT alone for hormone-sensitive newly metastatic prostate cancer.